Clinical Trials

3-D Matrix is selling its approved hemostatic agent PuraStat®  in Europe, Latin America and Southeast Asia and preparing investigational studies for FDA approval. In the United States, 3-D Matrix has successfully completed a pilot study to use PuraMatrix®  as a dental bone void filler. In Japan 3-D Matrix is currently completing trials for various clinical applications.


PuraMatrix® is a platform technology that can fulfill numerous clinical indications and therapeutic needs.



Find out the most recent developments at 3-D Matrix

Learn More


Learn how PuraMatrix® can enhance your technology

Learn More


Review the strong body of literature utilizing PuraMatrix®

Learn More